Select Language

HLA-A*0201 | B2M

Product Inquiry

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
LBL-019	LBL-019	Phase 2 Clinical		Neoplasms	Details
BI-1910	BI-1910	Phase 2 Clinical	Bioinvent International Ab	Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung	Details
BITR-2101	BITR-2101; BIR-2101; BITT2101; BITT-2101	Phase 1 Clinical		Infections; Neoplasms; Lymphoma, Non-Hodgkin	Details
NBL-020		Phase 1 Clinical	Shanghai Xinshi Biological Medicine Co Ltd	Solid tumours; Neoplasms	Details
SIM1811-03	SIM1811-03; SIM0235; SIM-235	Phase 1 Clinical	Jiangsu Simcere Pharmaceutical Co Ltd	Solid tumours; Neoplasms; Lymphoma, T-Cell, Cutaneous	Details
HFB-2003(HiFiBiO Therapeutics)	HFB-200301; HFB-2003	Phase 1 Clinical	HiFiBiO Therapeutics	Skin Melanoma; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Mesothelioma; Sarcoma; Testicular Neoplasms; Germinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis	Details

English Name	Research Code	Highest Development Stage	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indication	Clinical Trial
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)		Approved			Mainland China	Psoriasis; Arthritis, Rheumatoid; Spondylitis, Ankylosing	Hisun Biopharmaceutical Co Ltd	2015-04-09	Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis	Details